MedTrace Logo

Predicting Complications in Women With Toxaemia

NCT00175526 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 650

Last updated 2016-06-01

No results posted yet for this study

Summary

At present, the management of pre-eclampsia is guided by expert opinions that are not well-based on firm evidence. What is required is a clinical tool that can accurately determine a women's risk for adverse outcomes, and thereby reduce the risk for women while safely prolonging pregnancies remote from term (to improve fetal outcomes). This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. This severity score will be used clinically (to guide management) and in research (in both clinical trials and basic science research), and will provide an evidence base on which to build future practice, improving outcomes for pregnant women and their babies. In addition, this project is part of a three part strategy to better understand the mechanisms of disease in pre-eclampsia and to investigate a potential disease-modifying therapy, namely, recombinant human activated protein C.

Conditions

  • Toxemia

Interventions

BEHAVIORAL

preeclampsia

This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Peter von Dadelszen, MD · University of British Columbia

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Canada
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175526 on ClinicalTrials.gov